Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118847 | 0.87 | F10 (0.60) | F10PTGS2 | |
| SCHEMBL118728 | 0.86 | F10 (0.58) | F10PTGS2 | |
| SCHEMBL28407706 | 0.86 | F10 (0.59) | F10PTGS2 | |
| SCHEMBL19647435 | 0.86 | F10 (0.59) | F10PTGS2 | |
| SCHEMBL19647445 | 0.86 | F10 (0.62) | F10PTGS2 | |
| SCHEMBL1679321 | 0.85 | F10 (0.65) | F10PTGS2POLB | |
| SCHEMBL21929346 | 0.84 | GAA (0.67) | F10PTGS2POLBKDM4EMEN1 | |
| SCHEMBL5626886 | 0.82 | F10 (0.59) | F10PTGS2 | |
| SCHEMBL5624556 | 0.82 | F10 (0.59) | F10PTGS2 | |
| SCHEMBL5624569 | 0.82 | F10 (0.64) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4668614-B2 | — | — | 2011-04-13 | — | — | JP | claimed |
| JP-2006500369-A | — | — | 2006-01-05 | — | — | JP | claimed |
| EP-1558247-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 2005-08-03 | — | — | EP | claimed |
| WO-2004017963-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-03-04 | — | — | WO | claimed |
| CN-110746370-B | Preparation method of 4- (4-aminophenyl) morpholine-3-one | 新发药业有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-110746370-A | Preparation method of 4- (4-aminophenyl) morpholine-3-one | 新发药业有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2020019529-A1 | PREPARATION METHOD FOR 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE | 新发药业有限公司 | 2020-01-30 | — | — | WO | disclosed |
| US-8435989-B2 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX INC. (CA) | 2013-05-07 | — | — | US | disclosed |
| US-20130072680-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-8309547-B2 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2012-11-13 | — | — | US | disclosed |
| US-8101609-B2 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20110034465-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-02-10 | — | — | US | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
| EP-1558247-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004017963-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072680-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | VKORC1, VKORC1L1, TFPI | F10 20/4885PTGS2 1540/4885POLB 2185/4885 |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 8/4885PTGS2 1741/4885POLB 2527/4885 |
| US-20110034465-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | VKORC1, VKORC1L1, TFPI | F10 20/4885PTGS2 1540/4885POLB 2185/4885 |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 7/4885PTGS2 1762/4885POLB 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.